fluorescence recovery after photobleaching

Stages

1. 1.
   Define state-specific proteomic and post-translational signatures(functional_characterization)

   This stage is proposed to define discriminative molecular features of the pathological condensate state.

   Selection: state-specific proteomic and post-translational signatures

2. 2.
   Establish causality by acute clustering or dispersal of selected synaptic proteins(functional_characterization)

   This stage is proposed to establish causality after molecular signatures are defined.

   Selection: causal effects of acute synaptic protein clustering or dispersal

3. 3.
   Screen for compounds that restore liquid-like molecular mobility(broad_screen)

   This stage is proposed to identify compounds that reverse pathological rigidification by restoring mobility.

   Selection: restoration of liquid-like molecular mobility measured by FRAP

4. 4.
   Pursue selective clearance directed at drug-induced signatures(confirmatory_validation)

   This stage is proposed as a therapeutic strategy to clear the pathological condensate selectively.

   Selection: ability to selectively target drug-induced signatures for clearance

Steps

1. 1.
   Use proximity labeling to define state-specific signaturesmolecular-state profiling method

   Define proteomic and post-translational features specific to the pathological condensate state.

   The abstract presents signature definition first so later perturbation and targeting can focus on state-specific features.

2. 2.
   Acutely cluster or disperse selected synaptic proteins with optogenetic toolscausal perturbation method

   Establish causality for the proposed condensate mechanism.

   The abstract places causal perturbation after signature definition and before therapeutic screening.

3. 3.
   Screen compounds for reliquefaction using FRAP as the readoutmobility readout assay

   Identify compounds that restore liquid-like molecular mobility.

   The abstract positions compound screening after causal testing to search for interventions that reverse the pathological material state.

4. 4.
   Direct autophagy-tethering chimeras to drug-induced signatures for selective clearanceselective clearance construct strategy

   Clear the pathological condensate selectively using drug-induced signatures as targets.

   The abstract presents selective clearance as a downstream translational strategy after defining discriminative features and testing dynamics-focused interventions.

Stages

1. 1.
   Secretion from producing cells(functional_characterization)

   This stage captures the initial release event from producing cells.

   Selection: Visualize paracrine factor secretion directly by fluorescent protein tagging to ligand or indirectly by cleavage of transmembrane pro-ligands or plasma membrane fusion of endosomes.

2. 2.
   Diffusion through extracellular space(functional_characterization)

   This stage measures how secreted paracrine factors move through extracellular space after release.

   Selection: Study extracellular diffusion using FCS, FRAP, FDAP, and single-molecule tracking.

3. 3.
   Binding to target cells(functional_characterization)

   This stage links extracellular paracrine factors to engagement of target cells.

   Selection: Visualize target-cell binding using biosensors including GRAB sensors and FRET probes for receptor tyrosine kinases.

4. 4.
   Activation of intracellular signaling within target cells(confirmatory_validation)

   This stage confirms that paracrine factor binding is associated with downstream signaling responses in target cells.

   Selection: Monitor target-cell intracellular signaling using biosensors for second messengers and transcription factors.

Steps

1. 1.
   Visualize secretion from producing cells

   Capture the initial release of paracrine factors from source cells.

   Secretion is the first event in the four-stage sequence described by the review.

2. 2.
   Measure extracellular diffusion of released factors

   Track movement of paracrine factors after secretion.

   Diffusion follows secretion in the causal path from source-cell release to target-cell exposure.

3. 3.
   Visualize target-cell binding events

   Determine whether diffusing paracrine factors engage target cells.

   Binding is positioned after diffusion and before downstream intracellular activation in the review's stage logic.

4. 4.
   Monitor downstream intracellular signaling in target cells

   Associate target-cell engagement with downstream signaling outcomes.

   Intracellular signaling activation is the final stage after secretion, diffusion, and binding in the review's ordered framework.